AbbVie Inc (ABBV)

148.24
-2.34(-1.55%)
  • Volume:
    3,290,968
  • Day's Range:
    147.75 - 150.05
  • 52 wk Range:
    105.56 - 175.91

ABBV Overview

Prev. Close
150.57
Day's Range
147.75-150.05
Revenue
56.73B
Open
150.05
52 wk Range
105.56-175.91
EPS
6.97
Volume
3,290,968
Market Cap
261.97B
Dividend (Yield)
5.64
(3.75%)
Average Vol. (3m)
7,260,263
P/E Ratio
21.60
Beta
0.79
1-Year Change
31.27%
Shares Outstanding
1,767,110,083
Next Earnings Date
Jul 29, 2022
What is your sentiment on AbbVie?
or
Vote to see community's results!

AbbVie Inc News

AbbVie Inc Analysis

AbbVie Inc Company Profile

AbbVie Inc Company Profile

Employees
50000

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • bought some puts. looking for a nice break down.
    0
    • May have to cut dividend .
      7
      • It's no where even close to needing a dividend cut. It's payout ratio is 40% which is about average for biotech and pharma. That being said I wouldn't buy at current prices but having gotten in sub 100 I plan to ride it long term.
        0
    • Yes, all the way down below 100. Cheers
      1
      • On friday we are gonna have a new high after earning report
        1
        • Oh yes; you have it
          1
        • welp, this comment didn't age well. I'm gonna wait till this goes a bit up so I lose less on my call options 🤷‍♂️
          1
        • get into this solid company
          0
      • Finally. just all the way down under 100
        7
        • Why do you say that? Cheers.
          0
        • Under $100? Are you high right now? Forward P/E is at 13 right now, it’s underpriced. 🤣🤣🤣
          0
      • Why are we falling this steep today? Cheers.
        1
        • For the fiscal year ended 31 December 2021, Romeo Power Inc revenues increased 87% to $16.8M. Net income totaled $10M vs. loss of $7.6M. Revenues reflect Product revenues increase from $2.9M to $12.4M, Service revenues increase of 51% to $4.4M. Net Income reflects FV Adjustments of Financial Investments increase from $34.2M to $126.4M (income), OTHER EXPENSE decrease from $3.9M (expense) to $0K.
          1
          • 177 in few days coming
            1
            • May be tomorrow...
              0
          • Are we gonna hold at 16+
            0
            • I meant 160+....now I'm greedily looking for more.
              0
          • 160 feels real good.
            0